Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Inflammatory Breast Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × bemcentinib × Clear all
NCT05469178 2025-10-29

A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

BerGenBio ASA

Phase 1/2 Terminated
26 enrolled 13 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03184558 2021-11-09

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

BerGenBio ASA

Phase 2 Terminated
29 enrolled 10 charts
Breast

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡